INMD vs. NTUS, OM, CUTR, TMDX, ITGR, LIVN, CNMD, SLNO, BLFS, and ZYXI
Should you be buying InMode stock or one of its competitors? The main competitors of InMode include Natus Medical (NTUS), Outset Medical (OM), Cutera (CUTR), TransMedics Group (TMDX), Integer (ITGR), LivaNova (LIVN), CONMED (CNMD), Soleno Therapeutics (SLNO), BioLife Solutions (BLFS), and Zynex (ZYXI).
Natus Medical (NASDAQ:NTUS) and InMode (NASDAQ:INMD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, community ranking, institutional ownership, dividends, risk, profitability, media sentiment and valuation.
Natus Medical has a beta of 0.22, meaning that its stock price is 78% less volatile than the S&P 500. Comparatively, InMode has a beta of 2.2, meaning that its stock price is 120% more volatile than the S&P 500.
92.4% of Natus Medical shares are held by institutional investors. Comparatively, 68.0% of InMode shares are held by institutional investors. 1.2% of Natus Medical shares are held by insiders. Comparatively, 6.9% of InMode shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
InMode received 39 more outperform votes than Natus Medical when rated by MarketBeat users. However, 81.38% of users gave Natus Medical an outperform vote while only 75.12% of users gave InMode an outperform vote.
InMode has a net margin of 38.84% compared to InMode's net margin of 2.65%. Natus Medical's return on equity of 26.15% beat InMode's return on equity.
In the previous week, InMode had 3 more articles in the media than Natus Medical. MarketBeat recorded 3 mentions for InMode and 0 mentions for Natus Medical. Natus Medical's average media sentiment score of 0.84 beat InMode's score of 0.59 indicating that InMode is being referred to more favorably in the news media.
InMode has a consensus price target of $32.80, suggesting a potential upside of 71.46%. Given Natus Medical's higher possible upside, analysts plainly believe InMode is more favorable than Natus Medical.
InMode has lower revenue, but higher earnings than Natus Medical. InMode is trading at a lower price-to-earnings ratio than Natus Medical, indicating that it is currently the more affordable of the two stocks.
Summary
InMode beats Natus Medical on 13 of the 17 factors compared between the two stocks.
Get InMode News Delivered to You Automatically
Sign up to receive the latest news and ratings for INMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
